Array BioPharma Inc. (ARRY)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 13.06 / 47.98
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

February Trade Ideas Rundown: How'd We Do?

February Trade Ideas Rundown: How'd We Do?

A fresh look at all 17 ideas: the winners, the losers and the still to be determined.

An Aggressive Trade in Array Biopharma

An Aggressive Trade in Array Biopharma

Despite biotech losing a bit of its former headline grabbing attention, there are still plenty of great setups to be found.

Array BioPharma Seems to Be in a New Uptrend

Array BioPharma Seems to Be in a New Uptrend

I really like how these three charts are shaping up on Array.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Array Bio downgraded at JP Morgan

Array downgraded at Leerink

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.

Shark Bites: Market Responds With 'Deutsche Who?'

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Shark Bites: Not Much Reason to Buy in This Environment

Shark Bites: Not Much Reason to Buy in This Environment

I'm even staying away from the appealing stocks.

Array CEO: Partnerships Smart While Cancer Drug Develops

Array CEO: Partnerships Smart While Cancer Drug Develops

Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.

TSRX, CYTK, ARRY: 3 Stocks on TV

TSRX, CYTK, ARRY: 3 Stocks on TV

StockMarketMentor.com founder Dan Fitzpatrick details how to play three stocks Jim Cramer discussed on CNBC's "Mad Money" last night.

Stocks Under $10: Blossoming Biotech Play

Stocks Under $10: Blossoming Biotech Play

Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.

The Next Big Thing in Biotech: ASCO Conference

The Next Big Thing in Biotech: ASCO Conference

Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.